Can I confidently say to patients that a 3-year structured exercise program may save their lives? The CHALLENGE trial (part 2)

Why I would not (yet) implement the CHALLENGE strategy

Aug 7 • 

Timothée Olivier

15

2

The online BREAKING-ICE App© out in The Lancet Oncology !

Understanding Censoring in Kaplan-Meier Curves and Exploring Informative Censoring

Aug 2 • 

Timothée Olivier

18

5

July 2025

Does a 3-year structured exercise program save lives? Part 1

Can we challenge the CHALLENGE trial results?

Jul 31 • 

Timothée Olivier

13

April 2025

"LUNAR: Full Moon or Eclipse? An exploration into tumor treating fields in lung cancer"

This is the title of our new paper out in the Journal of Cancer Policy!

Apr 17 • 

Timothée Olivier

11

2

How to appraise the control arm in oncology trials, in 10 minutes!

From a recent virtual session I had the pleasure of giving at IOSI, Ticino, Switzerland.

Apr 11 • 

Timothée Olivier

21

10:03

March 2025

"Surrogate end points in oncology: the speed-uncertainty trade-off from the patients' perspective"

This is my new paper out in Nature Reviews Clinical Oncology

Mar 25 • 

Vinay Prasad

27

The 19th St Gallen Breast Oncology Conference begins on 12 March 2025 : "Should we combine adjuvant drugs that were tested in isolation in…

Our paper with Vinay Prasad is now published in the Journal of Cancer Policy – and it couldn’t be more timely!

Mar 9 • 

Timothée Olivier

10

1

The ‘Duck Test’ for Huey, Dewey and Louie: the legal case on CDK4/6 inhibitors

Me-too drugs (drugs with the same mode of action for the same indication) are generally beneficial to society as they provide variation, choice and…

Mar 6 • 

Sahar van Waalwijk

 and 

Hans Westgeest

23

CDK4/6 Inhibitors and Novel Adjuvant Therapies: Using Statistics to Inform Shared Decision-Making

Here is the talk I gave on March 3rd 2025 at the CRUK Cambridge Institute. Thanks again to Dr. Henno Martin and the team for the invitation and the…

Mar 4 • 

Timothée Olivier

16

5

1:01:48

February 2025

Vaccine Safety Research: Too Much Confounding and Spin.

In a systematic review, we found that authors of vaccine safety observational studies conceded residual confounding in about 75% of the studies…

Feb 25 • 

Mariana B. Caiado Ferreira

24

1

The CABINET study

100% NIH funded; 100% placebo controlled

Feb 21 • 

Vinay Prasad

27

3

19:17

Excessive Drug Price Leads to Hefty Fine for Company in the Netherlands

Why was a company fined €17 million for excessive pricing?

Feb 19 • 

Sahar van Waalwijk

21

1